Love Maharashtra? Then you wil love Marathikatta!
Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                    Movies   Aviation   Pharma   About Us   Feedback   Links
RANBAXY SALES
 

Overseas sales power Ranbaxy’s bottomline


BY OUR PHARMA CORRESPONDENT

30 April,2007: S

India’s top drug drug maker Ranbaxy Laboratories has registered record profits for the quarter ending March 2007, powered by soaring overseas business. The company’s global sales grew 23% resulting a 79% jump in net profits to the tune of Rs 128.70 crore from Rs 71.80 crore in the corresponding period of last year. Earnings per share on a fully diluted basis worked out to Rs 2.61 as against Rs 1.91 in the last period.

Emerging markets fueld 54% of global sales with a 53% growth in Q1 2007. This segment comprises amongst others, key countries of India, Romania, CIS, South Africa, Central & Eastern European nations, CIS and Latin America. The Developed Markets, primarily USA, Canada, countries in Western Europe and Japan recorded sales of USD 140 Mn, a growth of 7%. These markets comprise 39% of global sales. The company's international business recorded sales of USD 281 Mn, up 23% and contributed 79 % to total sales successful start in the European continent with key markets delivering strong growth. Sales in Europe up 78% to USD 93 Mn.

Sales in North America were at USD 91 Mn, recording an increase of 3%. For the quarter, USA recorded sales of USD 86 Mn, at similar levels to the corresponding previous quarter. Ranbaxy received approval for 4 ANDA's which included Zolpidem Tartrate Tablets, 5 /10 mg, Sertraline Hydrochloride Tablets 25/50/100/150/200 mg, Amoxicillin and Clavulanate Potassium Oral Suspension USP, 600 mg/ 5 ml and Valacyclovir Tablets 500 mg/ 1g. The combined innovator market size for these products is in excess of USD 6 Bn (Source : IMS).

Amongst the most significant ANDA approvals received recently was the US FDA approval for Pravastatin Sodium Tablets (Pravastatin), 10/ 20/ 40/ 80 mg, with a 180 days marketing exclusivity for the 80 mg dosage strength. The total annual market sales for all strengths stood at USD 1.19 Bn (IMS - MAT: December 2006) and for the 80 mg alone was at USD 209 Mn. The Company expects to garner a significant market share of the Pravastatin 80 mg product during the exclusivity period.

On the branded business, the key product Sotret (Isotretinoin) became the largest selling brand in its category garnering a market share of 36% (as against 22% in the corresponding previous period). The 30 mg strength has captured a 65% prescriptions market share in its represented category(Source : IMS).

Ranbaxy, presently, has 88 ANDA's pending approval with the US FDA. These products at an innovator market size are valued at USD 56 Bn and comprise a well-balanced mix of plain vanilla generics, niche & potential First to File products. The Company believes that it has a First to File status on approximately 20 Para IV ANDA filings, with an innovator market size in excess of USD 25 Bn.

Ranbaxy in Canada achieved the 9th position with a 1.2% market share of the total generics market and a 13% market share in the represented molecules (Source: IMS). During the quarter, the Company received approval to manufacture and market RAN(tm)-Cefprozil Tablets, 250mg and 500mg, and RAN(tm)-Cefprozil Powder for Oral Suspension, 250mg/5mL from Health Canada. The total market size for Cefzil(tm) in Canada was USD 25 Mn (IMS-MAT: Dec 2006).

In Q1 2007, Europe (including Romania) registered sales of USD 93 Mn, 78% higher than the corresponding previous period. The improved performance was a result of robust sales growth in most key EU countries. Subsequent to Romania joining the EU effective January 1, 2007, it becomes the Company's third largest market globally and the largest in Europe. Rest of Europe continued to exhibit buoyant growth led by the important markets of Spain, Italy and Poland.

Romania recorded sales of USD 37 Mn for the quarter, registering a growth of 50%. With the integration of Terapia into the Ranbaxy fold having been completed, the combined entity Terapia Ranbaxy in the quarter received marketing authorization for 20 new products to be launched in the coming months. It also obtained the new Manufacturing & Import Authorization as per EU norms and standards consequent to the alignment of the quality systems of Terapia Ranbaxy with EU norms. With a market share of 5.2%, Terapia Ranbaxy is ranked 6th in the marketplace. It has the largest field force of around 350 people and is the biggest generics producer in Romania.

Ranbaxy’s operations in the Western Europe countries of UK, Germany and France, recorded a combined turnover of USD 34 Mn for the quarter, registering a growth of 7%.

Sales in UK were at USD 12 Mn, an increase of 77% over previous year. While market conditions remained competitive, the restructuring undertaken in 2006, coupled with the launch of new products have resulted in a much-improved performance. The branded division performed well with the launch of Easyhaler Formoterol, adding to the Company's existing products in the respiratory segment.

Its German business recorded sales of USD 10 Mn, an increase of 11% over the corresponding previous period. 11 products of the Company's German subsidiary Basics GmbH were listed with AOK, Germany's largest health insurance Company, representing 35% of all health insurance policy holders in the country. The growth in Germany was despite stagnation in the market due to the recent regulatory changes. Based on highly competitive costs of India based supplies, the company is able to meet the requirements of the German market by operating at the lower price levels which is critical for future growth as compared with the top ranked companies with much higher costs coming from local setup & infrastructure.

Ranbaxy’s sales in rest of Europe were at USD 22 Mn, a growth of 46% over the corresponding previous period. The growth was led by robust performances in all markets including Poland, countries of Central Europe, Spain, Italy & Belgium. Spain registered sales of USD 4 Mn for the quarter while Poland recorded sales of USD 6 Mn, a growth of 52%.

The Asia Pacific & CIS region recorded combined sales of USD 115 Mn for the quarter, 32% better than the previous year. The performance was a result of the improved performances from all geographies, with the CIS region and India maintaining its strong growth momentum.

The sales for the quarter were at USD 65 Mn, 26% better than the corresponding previous period. In rupee terms, the India region sales grew by 24%. The growth was led equally by Acute and Chronic businesses, both growing in excess of 20%. During the quarter, the India business launched 18 new products. Restructuring of domestic operations in line with customer groups, coupled with high growth contribution from several new products introduced over the last year has fueled the business growth for Ranbaxy in India.

During MAT period February 2007 Ranbaxy has garnered 5.1% market share. Contribution of Chronic therapy portfolio to total sales stood at 23.6% (Moving Quarter February 2007) as against 22.0% over the corresponding period last year. Ranbaxy's Chronic Portfolio has grown faster than the market. (Source: ORG-IMS, February, 2007).

The contribution of the Novel Drug Delivery System (NDDS) portfolio to total Ranbaxy sales stood at 8.8% (Moving Quarter February 2007) and the Company continues to be the leader with a 7.7% market share in the NDDS segment. (MAT February 2007) (Source : ORG-IMS, February, 2007).

Ranbaxy has 20 brands in the top 300 brands with 9 brands featuring amongst the top 100 list. Amongst the new products introduced over the last one year, three of Ranbaxy's brands - Synasma (Oral anti-asthma), Cefditran (3rd generation cephalosporin) and Soliten (for treatment of overactive bladder) feature amongst the Top 30 brands of the Industry (MAT February 2007).

Ranbaxy launched 6 NDDS products in the last quarter. Two of these NDDS formulations have been launched in the Urology segment - Niftran 100mg Capsules (Nitrofurantoin modified release) developed using the Company's R&D capabilities & Eligard 22.5mg & 45mg (Leuprolide Depot), in-licensed from QLT Inc., USA.

It launched Osovair (Formoterol + Ciclesonide) inhalation capsules for the treatment of asthma, in India. This product further strengthens the Company's presence in this segment complementing its earlier novel launches in 2006 of Osonide (Ciclesonide) and Synasma (Doxophylline).

Recorded sales of USD 18 Mn (+61%) for the quarter. Russia & the Ukraine belt recorded sales of USD 9 Mn each with a growth of 71% and 51% respectively.

Asia Pacific (excluding India) registered sales of USD 24 mn, an increase of 33% over the previous period. The growth in the quarter was driven by an all round better performance from key markets such as the Middle East, Thailand, Malaysia, China and Japan.

The company's Global Consumer Healthcare Business recorded sales of USD 8 Mn, a growth of 26% over the corresponding previous year. Revital, the Company's flagship brand continues to perform well and has garnered a market share of 76.8% in its segment, up from 67.9% in the corresponding previous period. The business has recorded a healthy growth of 63% over last year (ORG - SSA Mat Feb '07).

Africa recorded sales of USD 24 Mn, a growth of 28%. The performance was led by key markets in Nigeria, Egypt and the countries in Central and South East Africa. The Company's core business in Africa (excluding the ARV business) grew at 30%..While South Africa recorded sales of USD 7 Mn, marginally higher than the previous period. Sales in Rest of Africa were USD 17 Mn, +42%.

Ranbaxy’s acquisition of Be-Tabs, the 5th largest branded generics Company in South Africa has received the necessary approval from the South African Competition Council. The Integration team is in place and work related to the alignment of the IT systems, Human Resources, Marketing & Sales and other support functions of Be-Tabs with Ranbaxy's existing functions are being firmed up.

Brazil registered sales of USD 6 Mn for the quarter, recording a growth of 14% over the corresponding previous period. The Company has maintained its Rank at # 6 in the generic market in Brazil.

During the quarter, Ranbaxy made an entry into Biosimilar segment by signing a global development & marketing agreement with a strategic partner in India, for its first biosimilar product, G-CSF (filgrastim). Ranbaxy will commit its resources to introduce the G-CSF product first in the EU markets and later in the US and other countries. The worldwide market for neutropenia treatment is in excess of USD 4 Billion, while the global G-CSF market is about USD 1.6 Bn.

The company also signed a term sheet with another strategic partner in India for a global supply agreement of Peptides. The aforesaid alliance will provide the Company with access to the fast growing & niche therapeutic segment of Peptides and will further strengthen the Company's product portfolio in the complex products category. Under the terms, Ranbaxy has the opportunity to acquire a strategic stake of 14.9%.

On research & development front Ranbaxy filed 3 ANDAs with the US FDA and received approval for 4 taking the cumulative filings to date to 199 with 111 approvals during the quarter. In the European Union (EU), the Company made 10 National filings in 9 Reference Member States (RMS) and received 9 approvals in 4 RMS.

In the area of NDDR, Ranbaxy achieved a significant milestone by entering into a multiyear collaboration with GSK that provides Ranbaxy expanded drug-development responsibilities and significant financial benefits. Under the new agreement, Ranbaxy will advance leads beyond candidate selection to completion of clinical proof of concept. GSK thereafter will conduct further clinical development for each program and take resulting products through the regulatory approval process to final commercialization. Ranbaxy could receive over USD 100 Mn in potential milestone payments for a product developed by Ranbaxy and subsequently launched by GSK in multiple indications and up to double digit royalties on worldwide net sales.

The joint team has recently approved the candidate selection of a compound for Respiratory Inflammation. Ranbaxy will take it forward to the pre-clinical stage. The Company will progress this drug candidate through pre-clinical studies needed to support an Investigational New Drug (IND) application and will be responsible for conducting Phase I and Phase II clinical studies through to Proof of Concept. GSK will then have the option to conduct further development through to final commercialization.

Also, Ranbaxy out-licensed its novel Statin NCE molecule to PPD, Inc. USA, the world's leading contract research organization. PPD will acquire the exclusive worldwide license to develop, manufacture and market the novel statin and Ranbaxy will be entitled to receive milestone payments upon the occurrence of specified clinical events and also receive royalties on sales of the drug and sales-based milestones, retaining co-marketing rights to the compound in India as and when commercialised.

"Robust growth across geographies driven by new product flow in most of our key markets has been the main theme this quarter. In particular, stellar performances in the Emerging Markets and the European Continent underpin the strong numbers, declared today. I expect this growth to continue and accelerate as we progress through the year,"commented Mr. Malvinder Mohan Singh, CEO and MD, Ranbaxy, in a press release.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 9 countries.

 

BY OUR PHARMA CORRESPONDENT

   

 

 

Auto news for auto freaks! iDrive.in
DWS community! / Cricket blog

 

Latest Stories in Pharma

 

Epilepsy cure with anti-dandruff shampoos

Overseas sales power Ranbaxy’s bottomline

Anti-smoking vaccine for nicotine addiction

Chemo sessions affect brain functions

DCA: A boon or bane?

MedImmune acquistion to bolster AstraZeneca’s drug pipeline

Novartis' Zelnorm recalled in US

Mood lifters no help in bipolar disorder

Hundreds of cancer cures in the offing

 

Pharma archive: 7 Jan 2007

Pharma archive: 14 Sep, 2005

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us